"On the safety front, all subjects experienced at least one serious treatment-emergent adverse event, most being chemo-related neutropenia or anemia. Serious (or greater) haNK-related adverse events occurred in two patients (fever and fatigue)."

"NantKwest (NASDAQ:NK) announces positive results from a Phase 1b clinical trial evaluating the combination of its antibody-targeted NK cells, ImmunityBio's N-803 (an IL-15 superagonist), low-dose chemo, adenoviral and yeast tumor-associated antigen vaccines (MUC1, brachyury, CEA) and a PD-L1 checkpoint inhibitor in patients with triple negative breast cancer (TNBC) who relapsed after prior treatment. The results were presented at the San Antonio Breast Cancer Symposium.

The overall response rate (ORR) in nine participants was 67% (n=6/9), including two complete responders. One patient experienced stable cancer implying a disease control rate of 78% (n=7/9). Durations of response ranged from 2-12 months. Median progression-free survival (PFS) was 13.7 months. Four patients remain on study."